» Articles » PMID: 16303004

Preemptive Plasmapheresis and Recurrence of FSGS in High-risk Renal Transplant Recipients

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2005 Nov 24
PMID 16303004
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Recurrent focal segmental glomerulosclerosis (FSGS) following transplantation is ascribed to the presence of a circulating FSGS permeability factor (FSPF). Plasmapheresis (PP) can induce remission of proteinuria in recurrent FSGS. This study addressed the efficacy of pre-transplant PP in decreasing the incidence of recurrence in high-risk patients. Ten patients at high-risk for FSGS recurrence because of rapid progression to renal failure (n = 4) or prior transplant recurrence of FSGS (n = 6) underwent a course of 8 PP treatments in the peri-operative period. Recurrences were identified by proteinuria >3 g/day and confirmed by biopsy. Seven patients, including all 4 with first grafts and 3 of 6 with prior recurrence, were free of recurrence at follow-up (238-1258 days). Final serum creatinine in 8 patients with functioning kidneys averaged 1.53 mg/dL. FSGS recurred within 3 months in 3 patients, each of whom had lost prior transplants to recurrent FSGS. Two of these progressed to end-stage renal disease (ESRD) and the third has significant renal dysfunction. Based on inclusion criteria, recurrence rates of 60% were expected if no treatment was given. Therefore, PP may decrease the incidence of recurrent FSGS in high-risk patients. Definitive conclusions regarding optimal management can only be drawn from larger, randomized, controlled studies.

Citing Articles

Genetic aspects of pediatric nephrotic syndrome and anti-nephrin antibodies.

Horinouchi T, Nozu K, Iijima K Clin Exp Nephrol. 2025; .

PMID: 40085383 DOI: 10.1007/s10157-025-02645-4.


Impact of Therapeutic Plasma Exchange and Rituximab for Prevention of Idiopathic Focal Segmental Glomerulosclerosis Recurrence Post-Kidney Transplantation.

Yun A, Rogers A, Krisl J, Kagan A, Adrogue H, Khan A Transplant Direct. 2025; 11(3):e1769.

PMID: 40034162 PMC: 11875572. DOI: 10.1097/TXD.0000000000001769.


Review of plasma exchange and rituximab for prevention of recurrent focal segmental glomerulosclerosis after a prior graft loss.

Gharaei S, Abbas H, Kanigicherla D World J Transplant. 2024; 14(4):98155.

PMID: 39697454 PMC: 11438932. DOI: 10.5500/wjt.v14.i4.98155.


Management and long-term outcome of recurrent idiopathic FSGS in pediatric kidney transplant recipients.

Plonsky-Toder M, Pollack S, Tibi R, Libinson-Zebegret I, Yaakobov R, Eisenstein I Sci Rep. 2024; 14(1):25493.

PMID: 39461970 PMC: 11513095. DOI: 10.1038/s41598-024-74184-z.


A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design.

Rheault M, Amaral S, Bock M, Chambers E, Chavers B, Ters M Front Nephrol. 2023; 3:1181076.

PMID: 37675355 PMC: 10479749. DOI: 10.3389/fneph.2023.1181076.